CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MultiVir Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MultiVir Inc
410 Pierce Street
Suite 325
Phone: (832) 431-3555p:832 431-3555 Houston, TX  77002-8757  United States Fax: (302) 655-5049f:302 655-5049
MultiVir Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-203086) with the SEC on 5/27/2015.
Business Summary
MultiVir Inc. is a clinical-stage gene therapy company. The Company develops a pipeline of product candidates for the treatment of multiple oncological indications. The Company's product candidate pipeline includes Ad-p53, Ad-IL24, Ad-VirRx 007, HSV-Rb-p450 and VV-IL12. Its Ad-p53 product candidate is a genetically modified adenovirus designed to deliver the normal p53 tumor suppressor gene, which targets fundamental molecular defects present in multiple types of cancers. Its Ad-IL24 product candidate is a genetically engineered adenovirus modified to deliver the tumor suppressor gene interleukin-24, which has tumor suppressor activities similar to p53 and certain immunostimulatory properties. Its product candidates has completed Phase I clinical trials as a monotherapy. Its Ad-VirRx 007 is an adenovirus-based product candidate. Its HSV-Rb-p450 is a herpes simplex virus-based product candidate. Its VV-IL12 product candidate is developed for the treatment of pancreatic cancer.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201412/31/2014YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board William P.Wells 55 12/1/2014 11/1/2009
President, Chief Financial Officer, Chief Operating Officer NicholasPuro 57 12/1/2014 2/1/2014
Chief Executive Officer, Director Robert E.Sobol 62 3/1/2012 11/1/2009
7 additional Officers and Directors records available in full report.

Business Names
Business Name
MDA7, Inc.
VirRx, Inc.

General Information
Outstanding Shares: 14,847,293 (As of 5/5/2015)
Stock Exchange: NASD
Federal Tax Id: 271253400
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023